-- 多倫多證券交易所午盤下跌180點,科技及材料板塊領跌,兩板塊均下跌4.0%。 週一公佈第一季獲利超出預期的Celestica (CLS.TO)股價午盤下跌15%,至488.00加幣。 能源和電信部門表現最佳,分別上漲2.6%和1.1%。 Telus (T.TO)今日稍早宣布與Technotree建立合作關係,股價上漲2.3%,成交量超過400萬股。 《環球郵報》報道稱,TD Cowen將Telus的評級從“持有”上調至“買入”。 根據加拿大廣播公司(CBC)新聞報道,聯邦政府將於今日下午4點公佈春季經濟報告,總理馬克·卡尼暗示經濟前景樂觀,赤字低於預期。預算觀察家預計赤字將有所下降。 公司新聞方面,巴里克礦業(ABX.TO)週二發布最新消息,計劃透過首次公開發行(IPO)出售其北美黃金資產持有的新公司的少數股權。對此,加拿大國家銀行表示,其維持對巴里克礦業的「跑贏大盤」評級,理由是該公司估值折讓、Fourmile項目未來進展順利以及北美資產即將實現的價值。 「Fourmile計畫的勘探進展是公司重要的價值驅動因素,鑑於先前宣布的馬裡Loulo-Gounkoto計畫已獲解決,這進一步支持了我們重新評估其評級。隨著公司重新聚焦於美洲(以內華達州為中心)黃金產量的增長以及營運的持續改進,我們認為未來其可持續估值有望實現更可持續的增長。」該銀行補充道。
Related Articles
US Treasury Closing Levels
3:00 Tuesday vs 3:00 Monday2yr 99-26 vs 100-04; 3.842% vs 3.799%5yr 99-16+ vs 99-21+; 3.981% vs 3.947%10yr 98-06+ vs 98-10+; 4.351% vs 4.335%30yr 97-00 vs 96-31+; 4.941% vs 4.941%2/10 50.633 bps vs 53.307 bps5/30 95.813 bps vs 99.249 bps
Brown & Brown's Q1 Report Shows Organic Revenue Growth Under Continued Pressure, UBS Says
Brown & Brown's (BRO) Q1 report shows that the company's organic revenue growth continues to remain under pressure despite better than expected quarterly earnings per share and adjusted margins, UBS said in a note.The company's flat Q1 organic revenue growth was below UBS expectations of a 2% growth and consensus of 1.3%, UBS said on Monday. The metric further excluded $10 million in litigation related lost revenue, which was in-line with expectations, according to UBS.Looking ahead, Brown & Brown expects catastrophe property rates to continue to experience downward pressure in Q2, while economic growth should remain relatively stable, UBS said. The company's capital allocation will have a bias toward buybacks and paying down debt, while remaining active for specialty and smaller deals, UBS added.UBS maintained its neutral rating on the company's stock with an $81 price target.Shares of Brown & Brown were down over 6% in Tuesday trading.Price: $62.07, Change: $-4.06, Percent Change: -6.13%
TD Cowen Raises Incyte Price Target to $124 From $123
Incyte (INCY) has an average rating of overweight and mean price target of $109.10, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $94.83, Change: $-0.89, Percent Change: -0.93%